Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV003422388 | SCV004139774 | uncertain significance | not provided | 2022-04-01 | criteria provided, single submitter | clinical testing | RTN2: PS1:Moderate, PS4:Moderate, BS1 |
Labcorp Genetics |
RCV003750788 | SCV004549909 | pathogenic | Spastic paraplegia | 2023-01-26 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Thr314Leufs*8) in the RTN2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RTN2 are known to be pathogenic (PMID: 22232211, 27165006). This variant is present in population databases (rs768449676, gnomAD 0.03%), including at least one homozygous and/or hemizygous individual. This premature translational stop signal has been observed in individual(s) with hereditary spastic paraplegia (PMID: 24123792). ClinVar contains an entry for this variant (Variation ID: 378054). For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV003422388 | SCV005079950 | uncertain significance | not provided | 2024-04-08 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene or region of a gene for which loss of function is not a well-established mechanism of disease; Reported in individuals with spastic paraplegia in published literature (PMID: 24123792, 32814230, 27165006); This variant is associated with the following publications: (PMID: 24123792, 25621899, 31589614, 28406212, 35684947, 32814230, 27165006, 34697415) |
OMIM | RCV000422203 | SCV000513412 | pathogenic | Hereditary spastic paraplegia 12 | 2017-03-02 | no assertion criteria provided | literature only |